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Abstract. 
 
Investigation of events committing cells to 
death revealed that a concealed NH
 
2
 
-terminal epitope 
of the pro-apoptotic protein Bak became exposed in
 
 
 
vivo before apoptosis. This occurred after treatment of 
human Jurkat or CEM-C7A T-lymphoma cells with the 
mechanistically disparate agents staurosporine, etopo-
side or dexamethasone. The rapid, up to 10-fold in-
crease in Bak-associated immunofluorescence was 
measured with epitope-specific monoclonal antibodies
 
 
 
using flow cytometry and microscopy. In contrast, using 
a polyclonal antibody to Bak, immunofluorescence was 
detected both before and after treatment. There were 
no differences in Bak protein content nor in subcellular 
location before or after treatment. Immunofluores-
cence showed Bcl-x
 
L
 
 and Bak were largely associated 
with mitochondria and in untreated cells they coimmu-
noprecipitated in the presence of nonioinic detergent. 
This association was significantly decreased after cell 
perturbation suggesting that Bcl-x
 
L
 
 dissociation from 
Bak occurred on exposure of Bak’s NH
 
2
 
 terminus. Mul-
tiple forms of Bak protein were observed by two di-
mensional electrophoresis but these were unchanged 
by inducers of apoptosis. This indicated that integration 
of cellular damage signals did not take place directly on 
the Bak protein. Release of proteins, including Bcl-x
 
L
 
, 
from Bak is suggested to be an important event in com-
mitment to death.
Key words: flow cytometry • etoposide • staurospo-
rine • dexamethasone • protein–protein interactions
O
 
ne
 
 of the central questions regarding the mecha-
nism of engagement of cell death is what biochem-
ical events irreversibly commit the cell to die?
These are likely to be changes that precede the execution
of the cell. It is also important to understand how signals
elicited by diverse toxic stimuli become integrated to ini-
tiate commitment to death. Because the suppressers of cell
death Bcl-2 and Bcl-x
 
L
 
 inhibit the toxicity of agents with
widely different modes of action (reviewed in 29, 42, and
44), it is considered that this family of proteins act at or
proximal to some critical point of the convergence of dam-
age signals and close to the point of commitment to
death. Recent evidence suggests that a Bcl-2-controlled ir-
reversible commitment to death is an event occurring be-
fore the so-called execution phase, characterized by the
apoptotic process. This essentially makes the commitment
to death an event that is separable from the process of
apoptosis itself, an idea that is receiving increasing sup-
port (1, 4, 26, 42).
Proteins of the Bcl-2 family have been suggested to in-
teract with each other to set a survival threshold for the
cell. These protein—protein interactions are presumed to
change as a cell commits to death (42) and enforced inter-
actions between Bax molecules have recently been shown
to be lethal (14). It might be predicted that disparate types
of cellular perturbation or damage would initiate changes
in the topology, thence the associations and thus function
of the pro- and anti-apoptotic proteins of the Bcl-2 family
and/or of associated proteins. Alterations in Bcl-2 family
protein conformation may include those that bring about
the proposed changes in the homodimerization and het-
erodimerization profiles of the promoters and suppressers
of apoptosis. It has been suggested that changes in the stoi-
chiometry of partner binding initiates an irreversible com-
mitment to cell death (22). However, from experiments in
vivo, which provided appropriate cellular contexts, it has
been shown that the pro- and anti-apoptotic Bax and Bcl-2
proteins may act independently of each other (21). In
some contexts it is possible that accessory proteins such as
Bad, Bid, and Bik, containing only a BH3 domain of the
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conserved Bcl-2 family homology domains, may serve as
intermediaries between the major suppressers and pro-
moters of apoptosis (19). Cumulatively, these proteins
may be essential components of what has been proposed
an Òapoptsat,Ó an integrator of pro- and anti-apoptotic sig-
nals, where cellular commitment to death or to survival oc-
curs before the activation of caspases (30).
The models whereby different patterns of homo- and
heterodimerization of Bcl-2 family members act to control
survival and death are based upon observations of pro-
tein—protein interactions using either the yeast two-hybrid
system or immunoprecipitation of tagged proteins from
cellular lysates in the presence of detergents (e.g., 16, 28,
32, 33, 45). Attempts to validate these findings have ex-
ploited site directed mutagenesis coupled with studies of
function, often after overexpression in a variety of cellular
backgrounds. Some of these studies have raised questions
regarding the requirements for direct protein—protein in-
teractions between the anti- and pro-apoptotic proteins
Bcl-2, Bcl-x
 
L
 
, Bax, and Bak (7, 35, 45). How Bcl-2 family
protein—protein interactions are regulated in response to
cellular perturbation and how they then proceed to pro-
mote or inhibit cell death is unclear. Recent data suggest
that posttranslational modifications of Bcl-2, specifically
phosphorylation, may play a role, at least as cells are in-
hibited in passage through mitosis (13, 15, 18, 24, 25). Ad-
ditionally, a change in phosphorylation of the BH3 domain
protein Bad appears in some cells to be a key component
linking survival signalling to the function of Bcl-x
 
L
 
,
 
 
 
so
that damage-induced changes in Bad phosphorylation
may affect survival (reviewed in 12). Presumably post-
translational modification results in protein conformational
changes affecting protein—protein interactions and subse-
quent activity. It has also been shown that in certain cellu-
lar contexts, but not all, cell damage leads to an increase in
the amount of proapoptotic family members, such as Bax
(27), and that survival signalling can increase the amounts
of anti-apoptotic molecules, such as Bcl-2 (31) or Bcl-x
 
L
 
(6, 37). However, changes in protein synthesis are not uni-
versal and appear to be the exception rather than the rule
(e.g., 5, 9).
Recently, in vitro experiments using cellular lysates
have investigated the interactions between the death sup-
presser Bcl-x
 
L
 
 and pro-apoptotic Bax protein. It was sug-
gested that the native state of Bax may be monomeric,
unbound to either Bcl-x
 
L
 
 or Bcl-2 (17). Using a set of
epitope-specific antibodies to different domains of the Bax
protein it was concluded that an NH
 
2
 
-terminal domain of
Bax (amino acids 12—24) is concealed unless detergent is
added, and that both homodimerization and its het-
erodimerization with Bcl-x
 
L
 
 only occur after a detergent-
induced conformational change. Questions were raised in
this study by Hsu and Youle (17) with respect to the valid-
ity of previous investigations where fusion proteins had
been used to study protein—protein interactions amongst
members of the Bcl-2 family as NH
 
2
 
-terminal fusions may
take on the detergent-induced conformation. The sugges-
tion was made that a change in conformation of the native
protein may be necessary to expose domains permissive
for interaction. In fact, the Bax—Bax interactions first re-
ported by Boise et al.
 
 
 
(3) were only obtained under condi-
tions where detergent manipulation was used. The results
of Hsu and Youle (17) suggest that Bax, and potentially
other members of this family of proteins, is dependent for
its interactions and possibly for its activity, on conforma-
tional changes involving domains at the NH
 
2
 
 terminus.
 
We considered that damage signals, generated after
toxin treatment of cells, could initiate conformational
changes in Bcl-2 family members to affect their function.
We wanted to establish whether any changes in conforma-
tion occurred in the native proteins (i.e., not tagged) in
intact cells exposed to disparate types of cell damage or
perturbation. Consequently, changes in antibody epitope
availability, which may reflect conformational change,
were monitored in single, drug-treated intact cells by flow
cytometry (FCM)
 
1
 
. Changes in immunofluorescence mea-
sured in this way might represent either changes in epitope
availability or in the amount of protein in the intact cell. A
direct comparison of Western blotting and flow cytometric
analysis of immunofluorescence using monoclonal or poly-
clonal antibodies to the pro-apoptotic protein Bak (11)
was performed. Critically, changes in immunofluorescence
were monitored before the appearance of apoptotic cells
as we were interested in the events which commit a cell to
death rather than its execution. FCM analysis showed that
NH
 
2
 
-terminal epitope-specific changes in Bak immunoflu-
orescence followed early after exposure to very disparate
toxic stimuli. This was associated with changes in protein–
protein interactions.
 
Materials and Methods
 
Cell Culture, Drug Treatment, and Analysis
of Apoptosis
 
The human Jurkat T-leukemic cell line was grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 2 mM 
 
L
 
-glutamine
(GIBCO BRL). The human CEM-C7A T-leukemic cell line was grown in
Optimem 1 medium (GIBCO BRL) supplemented with 5% FBS as were
the CEM-C7A cells stably transfected with Bcl-2 (CEM-Bcl-2) or an
empty control vector (CEM-Neo; reference 4). Cultures were incubated at
37
 
8
 
C in a humidified atmosphere of 5% CO
 
2
 
. Cells in a logarithmic phase
of growth were resuspended at a density of 3
 
 3 
 
10
 
5
 
 cells/ml in fresh me-
dium before drug treatment. Etoposide, staurosporine, and dexametha-
sone were purchased from Sigma Chemical Co. Stock solutions of drugs in
DMSO were stored at 
 
2
 
20
 
8
 
C. Control cells received solvent alone. The fi-
nal concentration of DMSO solvent in the culture medium never ex-
ceeded 1% (vol/vol), which was nontoxic to the cells. Mouse IgM anti-
CD95 monoclonal antibody (mAb; clone CH-11) was purchased from
Coulter Electronics Ltd. An irrelevant mouse IgM antibody (Coulter
Electronics Ltd.) was used as negative control. The morphological
changes of chromatin condensation, typical of apoptosis, were assessed by
fluorescence microscopy after staining of cells with acridine orange (10
 
m
 
g/ml) and the % apoptosis was scored after scoring at least 200 cells.
 
Analysis of Protein Expression by Western Blotting
 
After treatment, cells were washed twice in PBS, lysed in lysis buffer (50 mM
Tris, pH 7.4, 1 mM EDTA, 150 mM NaCl, 1 mM Na orthovanadate, 0.5%
NP-40, and protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml aprotinin, and 10 
 
m
 
g/ml trypsin inhibitor). Cell
lysates (30 
 
m
 
g protein) were separated by SDS-PAGE (12% acrylamide)
and transferred to a PVDF membrane (hybond-PVDF; Amersham Life
 
1. 
 
Abbreviations used in this paper:
 
 Cy3, indocarbocyanine; DMP, dimeth-
ylpimelimidate; FCM, flow cytometry; PFA, paraformaldehyde; zVAD-
fmk, 
 
N
 
-benzoylcarbonyl-Val-Ala-Asp-fluoromethylketone.
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Sciences). After blocking nonspecific binding sites overnight with 5%
nonfat milk in TPBS (PBS, 0.1% Tween-20), the membrane was incu-
bated for 2 h at room temperature with a 1/1,000 dilution of a murine anti–
human Bak monoclonal antibody designated as Ab-1 and raised against
the peptide sequence amino-acids 1–52 (AM03; Calbiochem-Novabio-
chem Ltd.), or Ab-2 (AM04; Calbiochem-Novabiochem Ltd.) also made
to the same peptide, or murine anti–human Bcl-2 mAb, made to a peptide
sequence of amino acids 41–54 (Dako Ltd.). To ensure equal loading and
transfer, membranes were also probed for actin using the anti-actin mouse
monoclonal AC-40 (Sigma Chemical Co.). The immunoreactive proteins
were visualized using rabbit horseradish peroxidase-linked goat anti–
mouse antibody (Dako Ltd.) and enhanced chemiluminescence (ECL;
Amersham Life Sciences).
 
Flow Cytometric Analysis of Bak and
Bcl-2-associated Immunofluorescence
 
At specific times after drug-treatment, cells (10
 
6
 
) were fixed in parafor-
maldehyde (PFA; 0.25%) for 5 min at room temperature and washed
three time in PBS. Cells were kept at 4
 
8
 
C until analysis, then centrifuged
and incubated for 30 min with the anti-human Bak monoclonal antibodies
Ab-1 or Ab-2, the anti-human Bcl-2 mAb (see above), a rabbit polyclonal
anti-human Bak antibody (66026E: raised against truncated protein lack-
ing the COOH terminus; PharMingen), or a mouse IgG2b isotype-specific
mouse antibody raised against
 
 Aspergillus niger
 
 glucose oxidase, desig-
nated as the irrelevant Ab (Dako Ltd.). All antibodies were diluted 1 in 50
in PBS containing digitonin (500 
 
m
 
g/ml). After three washes in PBS, cells
were incubated with FITC-labelled goat anti–mouse or anti–rabbit IgG
secondary antibody, diluted 1 in 100 in PBS, for 30 min, washed twice in
PBS and resuspended in 1 ml of PBS. Analysis was performed on a
FACS
 
®
 
 Vantage flow cytometer equipped with an Enterprise laser (In-
nova Technology, Coherent Inc.) set to excite at 250 mW using the 488-
nm laser line. Green fluorescence (FITC, FL-1) was detected at 530 
 
6
 
 30
nm. Fluorescence was acquired using logarithmic amplifiers. 10,000 cells
were analyzed per sample at a flow rate of 300 cells/s.
The effect of coincubation with the broad spectrum caspase inhibitor
zVAD-fmk (40 
 
m
 
M) on Bak Ab-1 (NH
 
2
 
-terminal) immunofluorescence
was analyzed by flow cytometric (FCM) in Jurkat cells before and after
exposure to etoposide and in CEM cells before and after treatment with
dexamethasone, both for 4 h.
CEM-Bcl-2 and CEM-Neo cells (4) were analyzed for immunofluores-
cence of Bak Ab-1 before and after exposure to etoposide for 4 h.
In order to quantitate the flow cytometric results obtained using Bak
Ab-1, the raw data obtained were manipulated in the following way: (a)
cells exhibiting a light scatter profile typical of apoptotic cells or cell de-
bris were excluded from the analysis by electronic gating; (b) the median
specific Bak-associated fluorescence (
 
f Bak
 
) was determined by subtrac-
tion of the median fluorescence of the parallel irrelevant antibody control
sample (
 
f IgX
 
; the fluorescence of samples containing secondary antibody
alone was closely similar to, and always less than 
 
f IgX
 
); (c) 
 
f Bak 
 
was mul-
tiplied by the percentage of cells with fluorescence above 
 
f IgX
 
 to gener-
ate a figure designated
 
 S
 
; (d) S
 
C
 
 for control untreated samples at a particu-
lar timepoint was subtracted from S
 
toxin 
 
for toxin-treated samples to
generate a final fluorescence value designated 
 
u
 
. The mean value of 
 
u
 
 was
determined in two or more separate repeat experiments.
 
Analysis of Cellular Bak and Bcl-x
 
L
 
 
Immunofluorescence by Microscopy
 
Control and etoposide-treated cells (10 
 
m
 
M) were fixed in PFA 0.25% for
5 min at room temperature and washed three times in PBS. Cells were in-
cubated overnight at 4
 
8
 
C with anti-human Bak mAb (Ab-1, specific to the
NH
 
2
 
 terminus) and/or anti-human Bak polyclonal antibody (pAb-Bak; for
details see above) and/or Bcl-x
 
L
 
 using the rabbit anti–human Bcl-x
 
L
 
 poly-
clonal antibody raised to residues 18–233 (pAb Bcl-x
 
L
 
; Transduction Lab-
oratories) diluted 1 in 50 in PBS-digitonin (500 mg/ml), washed in PBS
and then incubated with either a FITC-conjugated goat anti–mouse IgG
antibody diluted 1 in 100 in PBS or a goat anti–rabbit conjugated with in-
docarbocyanine (Cy3; Jackson Immunochemicals). Nuclei were stained
with a solution of Hoechst 33342 (1 
 
m
 
g/ml). Cells were then suspended in
Vectashield mounting medium (Vector Laboratories), pipetted dropwise
onto a glass slide and observed by fluorescence microscopy using a Zeiss
Axioskop microscope equipped with an epiilluminator and appropriate
filters.
 
Subcellular Localization of Bak and Other Proteins
 
Cells were washed twice in ice-cold PBS and then resuspended at 5 
 
3
 
 10
 
7
 
/ml
in ice-cold lysis buffer (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM
MgCl
 
2
 
, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 1 mM dithiothreitol,
0.5 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 10 
 
m
 
g/ml
aprotinin, and trypsin inhibitor 10 
 
m
 
g/ml). The cell suspension was homog-
enized in a Dounce homogenizer and centrifuged at 700 
 
g
 
 for 7 min at 4
 
8
 
C.
The pellet containing any remaining intact cells and nuclei (designated as
N) was washed once in lysis buffer and the postnuclear supernatant was
centrifuged at 10,000 
 
g
 
 for 15 min. The resulting pellet, designated P10,
was washed once in lysis buffer and the supernatant was subjected to ul-
tracentrifugation at 100,000 
 
g
 
 for 1 h to pellet the remaining membrane,
termed P100. The remaining supernatant was the cytosolic fraction (desig-
nated S100). The fractions N, P10, and P100 were resuspended in 1 vol of
lysis buffer. Each fraction was subjected to SDS-PAGE electrophoresis
and analyzed by Western blotting for Bak content. The relative purity of
fractions was ascertained by Western blotting using the mouse anti-cyto-
chrome oxidase IV mAb (Molecular Probes) as a marker of the mitochon-
dria, the rabbit anti-calnexin pAb and a rat anti-KDEL peptide (anti-
grp78) pAb (both from StressGen) as markers for endoplasmic reticulum,
the mouse anti–human poly(ADP-ribose)polymerase mAb (Serotec) as a
nuclear marker and the anti-procaspase-3 mAb (Transduction Laborato-
ries) and a rabbit anti-aldolase (a kind gift of Dr. C. Schnarrenberger,
University of Manchester, UK) to check the purity of the cytosolic frac-
tion.
 
Immunoprecipitations
 
Immunoglobulins were bound to protein A–Sepharose for 1 h at room
temperature in the Hepes buffer described below. Beads were sedimented
and washed twice with 10 vol of 0.2 M sodium borate, pH 9, then cross-
linked with 20 mM DMP for 30 min. Unreacted cross-linker was removed
by washing beads with 0.2 M ethanolamine, pH 8. They were resuspended
in PBS with 0.01% thimerosal (Sigma).
 
Jurkat cells were grown to a density of 10
 
6
 
 cells/ml and treated with eto-
poside (10 
 
m
 
M) for 20 h, to ensure maximum exposure of the NH
 
2
 
-termi-
nal epitope of Bak. Control cells received solvent alone. Cells (1.2
 
 3 
 
10
 
8
 
)
were washed with PBS and then lysed in 2 ml of 10 mM Hepes, pH 7.4,
150 mM NaCl, 0.1% NP-40, 40 
 
m
 
g/ml PMSF, 1 
 
m
 
g/ml leupeptin, and apro-
tinin. Lysis was carried out on ice for 30 min, with regular vortexing. A
post-nuclear supernatant was prepared by centrifugation at 10,000 
 
g
 
 for 10
min at 4
 
8
 
C. The resulting lysate was precleared with 200 
 
m
 
l of neat pig-
serum, DMP (dimethylpimelimidate) cross-linked to protein A—Seph-
arose (Pharmacia), rotated at 4
 
8
 
C for 1 h to remove nonspecific IgG bind-
ing proteins, and the protein A beads recovered by centrifugation at
10,000 
 
g
 
 for 5 min at 4
 
8
 
C. The supernatant was further cleared by the addi-
tion of 200 
 
m
 
l of protein A—Sepharose slurry (prepared by equilibrating in
Hepes buffer according to the manufacturers protocol, and resuspended
in two bed volumes), rotated at 4
 
8
 
C for 30 min, and removed by centrifu-
gation at 10,000 
 
g
 
 for 5 min at 4
 
8
 
C. The resulting cleared lysate was then
used for immunoprecipitation of Bak and Bcl-x
 
L
 
 proteins.
Immunoprecipitations were performed at 4
 
8
 
C for 1—3 h. There was no
significant difference in the results if these were left overnight. Each of the
antibodies used for immunoprecipitation were cross-linked with DMP (as
described above) onto the protein A—Sepharose media. Antibodies were
as described above. Both the monoclonal and the polyclonal antibodies
were used. In addition, mouse irrelevant (Dako X0931), and rabbit irrele-
vant (Dako X0903) antibodies were used as controls. The antibody/pro-
tein A—Sepharose matrix was sedimented before use to remove the stor-
age buffer (PBS/thimerosal); Ab-1 (10 
 
m
 
g) and Bcl-x
 
L
 
 (20 
 
m
 
g) antibodies
were added to 500 
 
m
 
l of lysate. The protein concentration for the Bak
polyclonal was unknown and was used at 30 
 
m
 
l per immunoprecipitation.
The immunoprecipitated proteins were recovered from the lysate by
centrifugation at 10,000 
 
g
 
 for 5 min at 4
 
8
 
C. The pelleted Sepharose was
washed 3 times with 1-ml vol of the Hepes buffer described above. The
immunoprecipitated proteins were eluted from the antibody—bead com-
plex by the addition of 100 
 
m
 
l of 3
 
3
 
 SDS-PAGE sample buffer. The beads
were vortexed thoroughly, sedimented at 15,000 
 
g
 
, and the supernatant
boiled before SDS-PAGE analysis, loading 30 
 
m
 
l per lane. The beads
could be boiled directly and no difference was seen in protein recovery.
However, in some instances immunoglobulin heavy chain was also eluted
from the beads. Lysates, precleared lysates, and immuno-precipitate-
depleted lysates were analyzed by SDS-PAGE and Western blotting, as
described above. The signals from the bands were quantitated using a Bio-
Rad GS-700 image densitometer with manufacturerÕs software.
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Two-Dimensional Gel Electrophoresis
 
Isoelectric focusing tube gels were prepared essentially as in Knowles
(20). Tube gels were prepared by water displacement and allowed to poly-
merize. These were prefocused for 1 h at 200 V. Treated or untreated cells
were lysed in urea sample buffer of 9 M urea, 2% ampholine 3-10, 100 mM
DTT, 4% NP-40, and 2% CHAPS (3-[(3-cholamidopropyl)dimethyl-
ammonio]-1-propane-sulfonate). 500 
 
m
 
g of protein was routinely loaded
per tube gel. Samples were then electrophoresed at 700 V for 16 h, then
fine focused for 1 h at 1,000 V. Gels were incubated in equilibration
buffer (0.5 M Tris-HCl, pH 6.8, 1 M glycerol, 1% SDS, with bromophenol
blue to color) for 10–15 min before overlaying onto a 15% polyacrylamide
slab gel. Two-dimensional electrophoresis was carried out followed by
Western blotting, as detailed above.
 
Results
 
Kinetics of Apoptosis
 
The kinetics of apoptosis of Jurkat and CEM-C7A lym-
phoma cells were characterized after exposure to stauro-
sporine, etoposide, and an agonistic antibody to CD95.
Dexamethasone-induced apoptosis in CEM-C7A cells was
also measured; the Jurkat cell line used did not respond
to dexamethasone. Table I summarizes the apoptotic re-
sponse of the two cell types to these agents acting at differ-
ent cellular loci. These were protein kinase inhibition by
staurosporine, protein-associated DNA single and double
strand breaks induced by etoposide (by inhibition of to-
poisomerase II), activation of a known death inducing re-
ceptor CD95, and activation of glucocorticoid receptors
and transcriptional changes by dexamethasone. Time-
points were then chosen for analysis of Bak content and
immunofluorescence before and after the appearance of
significant numbers of apoptotic cells.
 
Measurement of Bak Protein Content
 
Measurements of the cellular content of Bak were made
by Western blotting at various times in Jurkat and CEM-
C7A cells before and after the death-inducing stimuli. Bak
was constitutively expressed in both lines, as determined
by the use of the anti-Bak antibody Ab-1 (NH
 
2
 
-terminal).
The cellular content of Bak was unaffected by any of the
toxic stimuli over the entire time course (Figs. 1 and 2, top
panels). Two other antibodies to the Bak protein (another
monoclonal antibody to the NH
 
2
 
 terminus and the poly-
clonal, see Materials and Methods) similarly showed no
change in the amount of Bak protein by Western blotting
(data not shown). There was also no evidence for cleavage
of Bak in any experiments. There were also no changes in
Bcl-2 protein content in either cell line after toxin treat-
ment (Fig. 1). Actin was used as a loading control.
 
Epitope-specific Changes in Immunofluorescence of 
Bak after Treatment with Toxins Measured by
Flow Cytometry
 
FCM was used to determine whether there were changes
in the amount of immunofluorescence associated with Bak
using the two epitope-specific antibodies made to the NH
 
2
 
terminus of Bak (Ab-1 and Ab-2, see Materials and Meth-
ods). Although no changes were observed by Western
blotting (Fig. 1), it has been suggested elsewhere (2) that
Figure 1. Protein levels of Bak measured by Western blotting us-
ing the monoclonal antibody Ab-1 to Bak in CEM-C7A (A, top)
or Jurkat cells (B, top) after treatment with STS (250 nM) for the
times indicated. Blots for Bcl-2 and actin are also shown. The re-
sults are representative of three independent experiments. The
middle panels show FCM-generated frequency histograms of
Bak Ab-1-associated fluorescence in control, untreated cells
(filled histogram) and after STS treatment for 4 h (open histo-
gram). The histogram for the irrelevant antibody control (gray
line) is directly superimposable upon the control, untreated his-
togram. The bottom panels show equivalent data for Bcl-2-asso-
ciated fluorescence; the histogram for the irrelevant antibody is
in the first decade (not shown). Results shown are representative
of at least three repeat experiments.
 
Table I. Kinetics of Apoptosis Induced by Etoposide, 
Dexamethasone, Staurosporine, or Anti-CD95
Monoclonal Antibody (CH-11) in Jurkat and CEM-C7A
T-leukemic Cell Lines
 
Time of
treatment
Jurkat CEM C7A
AO apoptosis
 
h %
 
Control 0 1.2(
 
6
 
0.2) 0.3(
 
6
 
0.2)
Etoposide 4 7(
 
6
 
1) 1(
 
6
 
1)
24 53(
 
6
 
6) 81(
 
6
 
13)
Dexamethasone 24 ND 2(
 
6
 
3)
48 ND 50(
 
6
 
10)
Staurosporine 4 13(
 
6
 
3) 37(
 
6
 
9)
24 48(
 
6
 
9) 79(
 
6
 
12)
Anti-CD95 mAb 24 55(
 
6
 
3) 22(
 
6
 
6)
1 ng/ml
 
Percentage of apoptosis was assessed by fluorescence microscopy after acridine or-
ange (AO) staining of cells. Results are expressed as mean(
 
6
 
SD) of three indepen-
dent experiments.
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this may represent the limitations of a methodology which
is population averaged and thus masks cellular heteroge-
neity. Using FCM there can be two potential explanations
for changes in immunofluorescence: firstly they may in-
deed reflect changes in cell protein content, but secondly
they may identify changes in epitope availability in intact
cells without a change in protein content. The flow cyto-
metric data shown are displayed as frequency histograms
of Bak immunofluorescence, detected using a FITC-conju-
gated secondary antibody. The data are presented on a
logarithmic scale and a shift to the right in the histogram
indicates an increase in Bak-associated immunofluores-
cence. Fluorescence associated with Bak Ab-1 or Ab-2
(NH
 
2
 
-terminal specific) was undetectable in intact un-
treated cells by flow cytometry and the histograms are
superimposed upon those of an irrelevant antibody con-
trol (Fig. 1, middle). Bak Ab-1-associated immunofluores-
cence became detectable 4 h after treatment of both cell
lines with staurosporine (STS; 250 nM; Fig. 1, middle).
Similar results were obtained using Bak Ab-2. There was
no change in the immunofluorescence associated with Bcl-2
using an antibody to amino acids 41–54 (Fig. 1, bottom).
Similarly, treatment with etoposide (10 
 
m
 
M) that irre-
versibly commits 
 
.90% of CEM-C7A cells to a loss of
clonogenic survival after 30 min of exposure (data not
shown), resulted in the appearance of Bak Ab-1 NH2-ter-
minal-associated immunofluorescence by 4 h, without any
increase in the amount of protein, measured by Western
blotting (Fig. 2 A). This was also seen with Jurkat cells
(Fig. 2 B). The increase in NH2-terminal epitope availabil-
ity at 4 h was dependent on the concentration of etoposide
added to Jurkat cells (Fig. 2 B). Thus increased amounts of
etoposide-induced DNA damage, and presumably some
DNA damage signal, induced more Bak immunofluores-
cence associated with an NH2-terminal epitope of the pro-
tein. Again, analysis of Bcl-2-associated immunofluores-
cence, showed this to be unchanged after etoposide, as it
was after STS treatment (compare Figs. 1 and 2). In all
FCM experiments, cell debris, the cells that were overtly
apoptotic at 4 h and cell aggregates were all electronically
excluded (gated out) by virtue of altered light scatter sig-
nals, before examination of the Bak immunofluorescence
profile. This may not remove all apoptotic cells, particu-
larly those in the early stages. Nevertheless, the changes in
Bak-associated immunofluorescence did not appear to be
associated with the apoptosis per se, that is, with the
execution phase of cell death (see also Table I). Some
type of apoptosis-associated proteolytic cleavage of Bak
to change epitope availability is also unlikely as we saw no
change in the size of Bak protein on the Western blots
(Figs. 1 and 2).
Dexamethasone also Changes Bak Ab-1 
Immunofluorescence but Ligation of CD95
(Fas, APO-1) Does Not
The immunofluorescence profiles for Bak were examined
after the addition of other death stimuli. Fig. 3 A shows
that the non-genotoxic drug dexamethasone revealed the
Bak Ab-1 epitope in CEM-C7A cells. In contrast, CEM-
C7A cells treated with an agonistic antibody to the CD95/
Fas/APO-1 receptor did not exhibit Bak immunofluores-
cence (Fig. 3 B) despite the induction of 22% apoptosis
(Table I). Similar results were obtained after treatment of
Jurkat cells with the anti-CD95 antibody (data not shown).
Exposure of the NH2-terminal Epitope of Bak Occurs 
before Caspase Activation
In experiments using the broad spectrum caspase inhibitor
zVAD-fmk, there was no effect on the increase in Bak-
associated immunofluorescence (Fig. 3 C). Data were
quantitated using an equation to derive the parameter u
(see Materials and Methods and below). The u values were
583 6 123 and 578 6 120 (n 5 3) for cells treated with eto-
poside in the presence or absence of zVAD-fmk, respec-
tively. The caspase inhibitor effectively inhibited apoptosis
in etoposide-treated cells to 6 6 3% (n 5 3).
Figure 2. Protein levels of Bak measured by Western blotting us-
ing the monoclonal antibody Ab-1 to Bak in CEM-C7A (A, top)
or Jurkat cells (B, top) after treatment with etoposide (10 mM)
for the times indicated. Blots for Bcl-2 and actin are also shown.
The results are representative of three independent experiments.
The middle panels show FCM-generated frequency histograms
of Bak Ab-1-associated fluorescence in control, untreated cells
(filled histogram) and after etoposide treatment for 4 h (open
histogram). The histogram for the irrelevant antibody control is
directly superimposable upon the control, untreated histogram.
The frequency histograms for Jurkat cells treated with two con-
centrations of etoposide (5 and 10 mM) are shown in the middle
right panel. The bottom panels show equivalent data for Bcl-2-asso-
ciated fluorescence; the fluorescence of the irrelevant antibody is
in the first decade (not shown). Results shown are representative
of at least three repeat experiments.
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Immunofluorescence Using a Polyclonal Antibody to 
Bak Is Detectable before and after Cell Perturbation
Critically, using the polyclonal antibody to Bak (pAb),
raised against all but the transmembrane domain of the
protein, immunofluorescence was detectable by FCM in
both untreated and etoposide-treated cells (Fig. 3 D). A
decade increase in fluorescence above that of the irrele-
vant antibody control was observed, with a slight increase
after etoposide treatment. Further comparison of data ob-
tained with the monoclonal and polyclonal antibodies is
described below in Fig. 5. The ability of the polyclonal an-
tibody (pAb) but not Bak Ab-1 antibody to bind Bak in
untreated cells supports the idea that a selective change in
epitope availability is occurring specifically at the NH2 ter-
minus of Bak after disparate toxin treatment and that this
epitope is concealed in untreated cells. Additionally, the
lack of change in immunofluorescence associated with
Bcl-2 also supports the idea of a specific damage-induced
change at the NH2 terminus of Bak and not that this was
an artefact of FCM.
Quantitation of Changes in
Bak-associated Immunofluorescence
The changes in immunofluorescence measured by flow cy-
tometry were quantified using an equation (see Materials
and Methods) that essentially determines the area under
curve (histogram) after subtraction of nonspecific fluores-
cence signals detected using an irrelevant antibody control
to generate a value termed u. The absolute increase in Bak
Ab-1 immunofluorescence, calculating a u value as de-
scribed above, was different in magnitude for etoposide,
STS and dexamethasone (Fig. 4), possibly reflecting differ-
ences in the kinetics of commitment to and onset of apop-
tosis, as discussed by us previously (40). For example, we
have found that while STS induces changes in immunoflu-
orescence throughout the cell cycle, etoposide does this
only at specific cell cycle phases, presumably reflecting cell
cycle checkpoint-associated signals (manuscript in prepa-
ration).
Bak Ab-1-associated immunofluorescence was detected
in both CEM-Neo and CEM-Bcl-2 cells after treatment
with etoposide. In two preliminary experiments, four
hours after drug treatment the u values for Bak Ab-1-asso-
ciated immunofluorescence were 154 and 160 for the
CEM-Bcl-2 cells compared with 216 and 210 for the CEM-
Neo cells.
Microscopy Confirms that the Exposure of the Bak 
NH2-terminal Epitope Is a Specific Event Occurring 
before Apoptosis
In order to test the hypothesis further that the NH2-termi-
nal epitope of Bak is exposed after perturbation but be-
fore the appearance of an apoptotic morphology, we ex-
posed Jurkat cells to toxins and compared by microscopy
the immunofluorescence of Bak Ab-1 and nuclear mor-
phology by costaining with Hoechst 33342 (Fig. 5 A). Un-
treated cells did not stain positively for Bak using Bak Ab-1
(not shown), confirming the FCM data. Three patterns of
Figure 3. (A) FCM-generated frequency histograms of Bak Ab-
1-associated fluorescence in CEM-C7A control, untreated (filled
histogram) and after dexamethasone treatment for 24 h (open
histogram). (B) FCM-generated frequency histograms of Bak
Ab-1 after an anti-CD95 agonistic antibody (open histogram su-
perimposed on control data). (C) FCM-generated frequency his-
tograms showing absence of change in the increase in Bak Ab-
1-associated immunofluorescence after staurosporine (STS; 250
nM for 4 h) with or without the caspase inhibitor zVAD-fmk (40
mM; filled histogram, irrelevant antibody; overlapping grey his-
tograms, STS 6 zVAD-fmk. (D) FCM-generated frequency
histograms of Bak polyclonal antibody (pAb)-associated Cy3
fluorescence for control, untreated (filled histogram) and etopo-
side-treated cells (10 mM for 4 h; open histogram, in the second
decade). The irrelevant antibody control is in the first decade
(open histogram). In A—C the histogram for the irrelevant anti-
body control is directly superimposable upon the histogram for
untreated cell. In D the irrelevant antibody is visible in the first
decade. Results shown are representative of at least three repeat
experiments.
Figure 4. Quantitation of the increases in Bak Ab-1-associated
fluorescence after treatment with various toxins as indicated us-
ing the equation for u described in Materials and Methods.
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staining were observed 4 h after cells had been treated
with etoposide (Fig. 5 A): there were some cells with an in-
tact, non-apoptotic nucleus which remained Bak Ab-1
negative (a); others had an intact nucleus but stained posi-
tively for Bak Ab-1 (b). The remainder displayed Bak Ab-1
staining and exhibited fragmented and condensed chroma-
tin (c). These data confirm that Bak Ab-1 fluorescence is
induced before morphological indications of apoptosis,
characterized by a loss of nuclear integrity. Fig. 5, B and C
show Jurkat cells dual stained with both the polyclonal
Bak antibody (red) and the Bak Ab-1 (green). B shows an
untreated cell: it displays only polyclonal antibody red flu-
orescence in a punctate distribution. C shows a typical eto-
poside-treated Jurkat cell with predominantly yellow fluo-
rescence indicating that at 4 h after drug treatment, the
majority of Bak protein molecules appear to be dual
stained with both antibodies. However, at this time, some
Bak molecules remain detectable only by the polyclonal
antibody. This may indicate the presence of different pools
and/or isoforms of Bak which possess different antibody
binding profiles (discussed further below). The staining is
no longer punctate, implying the compaction of the mito-
chondria in a reduced cytoplasm, an established feature of
apoptotic cells.
Colocalization of Bak and Bcl-xL by
Fluorescence Microscopy
To determine whether Bak and Bcl-xL were colocalized in
etoposide-treated Jurkat cells, cells were dual stained with
Bak Ab-1 visualized with a FITC tagged secondary anti-
body (green) and with Bcl-xL pAb visualized with a Cy3
tagged secondary antibody (red). It was not possible assess
colocalization before etoposide treatment since the Bak
Ab-1 epitope was unavailable (see Fig. 2) nor was it possi-
ble to dual stain with polyclonal antibodies for reasons of
secondary antibody overlap. Fig. 6 A shows a typical un-
treated cell exhibiting Bcl-xL immunofluorescence but no
Bak Ab-1 staining. 4 h after etoposide treatment the cell
population is heterogeneous, comprised of cells with intact
nuclei and cells with fragmented nuclei and condensed
chromatin. In Fig. 6 B, in a cell that has not yet undergone
apoptosis, Bcl-xL pAb and Bak Ab-1 are predominantly
colocalized (observed as yellow fluorescence). In Fig. 6 C,
where the cell is clearly apoptotic, the degree of colocal-
ization appears to be decreased.
Subcellular Localization of Bak Protein after STS
The change in Bak immunofluorescence induced by eto-
poside and other agents represents the exposure of an oth-
erwise cryptic epitope at the NH2 terminus. This suggested
the possibility that like Bax protein, which moves from cy-
tosol to mitochondrial membranes on exposure of its NH2
terminus (39), Bak may also change its cellular location
following a damage signal. Therefore, we attempted to in-
vestigate the subcellular location of Bak and whether it
was translocated in Jurkat cells after STS using cell frac-
tionation methods similar to those used previously (36,
39). However, we were concerned about the purity of the
mitochondrial (P10) and endoplasmic reticulum (P100)
enriched fractions using these methods and consequently
Figure 5. Analysis of Bak-
associated immunofluores-
cence and nuclear morphol-
ogy using fluorescence
microscopy after treatment
with etoposide (10 mM) for
4 h. (A) Bak Ab-1-associ-
ated fluorescence was visu-
alized using an FITC-conju-
gated secondary antibody
(green) and nuclear mor-
phology was assessed by
Hoechst 33342 staining
(blue). (a) Cell with an in-
tact nucleus and no Bak Ab-1
staining. (b) Cell with an in-
tact nucleus but which show
Bak Ab-1 staining. (c) Cell
with a condensed and
fragmented nucleus and
Bak-associated Ab-1 fluo-
rescence. (B) A control, un-
treated Jurkat cell dual
stained with Hoechst 33342
and Bak polyclonal anti-
body (red). (C) An etopo-
side-treated Jurkat cell tri-
ple stained with Hoechst
33342, Bak polyclonal antibody (pAb; red) and Bak Ab-1 (green). Coincident staining for Bak Ab-1 and Bak pAb resulted in yel-
low fluorescence. Results shown are representative of three repeat experiments.
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examined markers for each fraction. This showed that, us-
ing these methods, P10 and P100 both contained calnexin
and grp78, both indicative of the presence of endoplasmic
reticulum. Additionally, there was also some contamina-
tion of the nuclear fraction by the endoplasmic reticulum.
However, procaspase 3 and aldolase were only present in
the cytoplasmic fraction (S100). It is thus only possible to
conclude that Bak protein was absent from the cytosolic
fraction, before and after STS treatment, and that it was
membrane associated (Fig. 7 A). Importantly, this differs
from reports of the location of the congener Bax which
is claimed to be cytosolic before signals which initiate
apoptosis (17, 39). Due to the lack of purity in cellular sub-
fractions generated by this protocol we also examined the
cellular location of Bak and Bcl-xL by fluorescence micros-
copy using organelle markers. Fig. 7 B shows that Bcl-xL
and Bak predominantly colocalized with the mitochon-
drial marker cytochrome oxidase IV and that neither Bak
nor Bcl-xL colocalized with the endoplasmic reticulum
markers grp78 or calnexin, supporting the idea of mito-
chondrial association for both molecules.
Assessment of Changes in Binding of Bak to Bcl-xL 
before and after Toxin Treatment
We considered that the exposure of the NH2-terminal
epitope of Bak after cellular perturbation might represent
a conformational change and/or the release of a Bak bind-
ing partner to change epitope availability. Since Bcl-xL has
been shown to bind to Bak (7, 8, 11, 35) and we have
shown that they colocalized in Jurkat cells by immunofluo-
rescence (see above), we examined whether these two pro-
teins were physically bound in untreated cells and whether
their association was altered by toxin treatment. Immuno-
precipitations were carried out using the Bcl-xL polyclonal
antibody, the polyclonal Bak antibody (which binds Bak in
the presence and absence of toxin treatment), and Bak
Ab-1 (NH2 terminus, which only binds to Bak after toxin
treatment). In initial experiments we attempted to coim-
munoprecipitate Bak with Bcl-xL in the absence of any de-
tergent, which would mimic the conditions used for FCM
where cells are fixed before detergent is added. Hsu and
Youle (17) cautioned that the use of detergents in proto-
cols for the immunoprecipitation of Bcl-2 family members
might initiate conformational changes promoting altered
patterns of protein—protein interactions. However, we
were unable to immunoprecipitate either Bak or Bcl-xL in
the absence of detergent, as the proteins were not solubi-
lized from the membrane fraction.
Using a low concentration of detergent (0.1% NP-40) it
was possible to immunoprecipitate Bak using the Ab-1
NH2-terminal antibody in control untreated cells (Fig. 8).
Using Bak Ab-1 there was no difference in the ability to
immunoprecipitate Bak comparing untreated cells with
those treated with etoposide for 20 h to maximize epitope
exposure at the NH2 terminus (Fig. 8). These data are in
contrast to the inability to detect Bak using this antibody
in untreated cells by FCM and microscopy (Figs. 1, 2, and
4) and most likely reflect the ability of detergent to expose
the Bak Ab-1 epitope. Immunoprecipitations performed
Figure 6. Immunofluores-
cence of Bak (Ab-1) visual-
ized with a FITC-tagged sec-
ondary antibody (green) and
Bcl-xL (pAb) visualized with
a Cy3 tagged secondary anti-
body (red) in Jurkat cells
with or without etoposide (10
mM) for 4 h. (A) Untreated
cells with an intact nucleus
and staining for Bcl-xL,
showing no immunofluores-
cence associated with Bak
(NH2-terminal epitope cryp-
tic). (B) Treated but pre-
apoptotic cell with an intact
nucleus showing substantial
overlap in location of Bak
and Bcl-xL. (C) Etoposide-
treated apoptotic cell, with
fragmented nucleus showing
less overlap of Bak and
Bcl-xL signals.
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using a monoclonal or polyclonal antibody to Bak, or a
polyclonal antibody to Bcl-xL showed that Bak and Bcl-xL
were constitutively associated in control, healthy cells
(Fig. 8). Analysis of the immunoprecipitates and superna-
tant lysates showed that using the Bak polyclonal antibody
100% of Bak was bound to Bcl-xL. In contrast, analysis of
the supernatants after immunoprecipitation with the Bak
pAb showed that z40% of Bcl-xL remained unbound to
Bak and was therefore in excess. When these immunopre-
cipitations were performed using etoposide-treated cells,
the association between Bak and Bcl-xL was clearly re-
duced (Fig. 8). In two independent experiments where we
obtained very clearly defined bands after Western blot-
ting, densitometry showed that a 30% and a 41% reduc-
tion of binding had occurred. The irrelevant antibody con-
trols indicate that immunoprecipitations were epitope
specific and not due to the type of immunoglobulin used
(data not shown).
Bak Exists in Multiple Isoforms Identified by
Two-Dimensional Gel Electrophoresis and Is 
Unchanged after STS Treatment
To establish whether the changes in Bak NH2-terminal-asso-
ciated immunofluorescence were associated with a post-
translational modification of Bak, we performed two-
dimensional electrophoresis and Western blotting for Bak
after treatment of Jurkat cells with STS, which produced
the most substantial change in epitope availability. Fig. 9
shows that Bak exists in multiple forms based on charge
differences in untreated cells, without major changes in
mass. There were no discernible changes in protein mobil-
Figure 7. (A) Distribution of Bak in subcellular fractions from
Jurkat cells measured by Western blotting. Subcellular fractions
were enriched in: N, nuclei; P10, mitochondria; P100, endoplasmic
reticulum (ER); and S100, cytosol. Purity of the fractions was ex-
amined using markers of these organelles (cytochrome oxidase
for mitochondria, calnexin, and grp78 for ER, and procaspase 3
and aldolase for cytosol). Results shown are representative of
three repeat experiments. (B) Images of the immunofluorescence
of Bak and from marker molecules characteristic for various sub-
cellular compartments. a, grp78 (green); b and c, Bak pAb (red);
d, cytochrome oxidase IV (green); e and f, Bak pAb (red); g,
grp78 (green); h and i, Bcl-xL, (red); j, cytochrome oxidase IV
(green); k and l, Bcl-xL, (red).
Figure 8. Investigation of the
association of Bak with
Bcl-xL. Immunoprecipita-
tions were performed using
0.1% non-ionic detergent
(NP-40) before or after treat-
ment of Jurkat cells with eto-
poside. The antibodies used
are shown and are as de-
scribed in Materials and
Methods. The subsequent
Western blots of the immunoprecipitated proteins were probed
with either an antibody to Bcl-xL (upper panel) or to Bak (lower
panel).
Figure 9. Representative Western blots from two-dimensional
gel electrophoresis of cell lysates from control, untreated Jurkat
cells, and those treated with STS (250 nM for 4 h), probed with
anti-Bak mAb-1. The numbers show what were considered to be
either discrete protein spots (1 to 7) or a group of unresolved
proteins (8).
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ity observed after STS treatment. Taken together, protein
spots before or after treatment at positions 1 to 6 were
very reproducible. However, the more acidic proteins at
positions 7 and above were more variable from sample to
sample, even in untreated cells, and we cannot exclude the
possibility that subtle changes may be occurring which we
are unable to resolve sufficiently. This is the subject of fur-
ther experimentation. Similar data were obtained when
cells were treated with etoposide.
Discussion
We have found that very different types of cellular pertur-
bation, all of which induced apoptosis (Table I), brought
about exposure of a specific epitope at the NH2 terminus
of the Bak protein. The epitope was completely concealed
from antibodies raised to the NH2 terminus in untreated
cells (Figs. 1 and 2). Importantly, the damage-induced ex-
posure of the epitope occurred before detection of both
morphological and biochemical changes typical of apopto-
sis. This is particularly exemplified by the 24 h data for
dexamethasone (Fig. 3 A) where we showed previously
that caspase activity was undetectable until after 30 h of
exposure (4). These alterations in Bak-associated immu-
nofluorescence induced by dexamethasone also preceded
the changes in mitochondrial membrane potential, occur-
ring before caspase activation (4). Thus, the change in the
availability of the NH2 terminus of Bak is not a component
of the execution phase per se, but presages it and is an
early indicator that the cells had been perturbed or dam-
aged. The specificity of this change in epitope availability
was indicated by the findings that while the two different
antibodies to the NH2 terminus showed significant changes
in immunofluorescence (Fig. 5 and Results), this was not
observed when a polyclonal antibody was used (Fig. 3 D).
The observation that totally disparate types of cellular
perturbation initiated this change also suggests that either
Bak itself or an associated molecule was acting as an inte-
grator of damage signals arising from different types of
disturbance in the cell, generated at different locations.
The change in epitope availability observed here in lym-
phoid cells has been reproduced for Bak in both neuronal
and epithelial cell lines and for an NH2-terminal epitope of
Bax in a B cell lymphoma line (our unpublished data).
In experiments where cells were treated with etoposide,
which rapidly commits them to apoptosis, simultaneous
probing with both the polyclonal and NH2 terminus—tar-
geted monoclonal antibodies to Bak showed that the im-
munofluorescence mostly overlapped (Fig. 6). There was a
small proportion of Bak, recognized by the polyclonal an-
tibody, that did not show toxin-induced exposure of the
Bak NH2 terminus. Whether this was a temporal phenom-
enon, arising from the cell cycle specificity of the damage
signals generated by etoposide, or whether this represents
some subpopulation of the Bak protein remains to be de-
termined. Immunoprecipitation showed that, in the pres-
ence of some detergent, all of the Bak was bound to Bcl-xL
but this does not preclude heterogeneity. As discussed be-
low, Bak protein is present in multiple, posttranslationally
modified forms and it is possible that only some of these
represent the active species, with others forming latent or
inactive subpopulations, perhaps in the complex with Bcl-xL.
Interestingly, the ligation of CD95, an effective initiator
of apoptosis (Table I) did not bring about a change in the
availability of the epitope at the NH2 terminus of Bak (Fig.
3 B). This suggests that ligation of CD95 (APO-1/Fas)
must act in some other way from the other toxins used to
stimulate cell death. Whereas CEM-C7A cells transfected
to overexpress bcl-2 were afforded significant delay in the
onset of apoptosis induced by etoposide, and complete
protection of the loss of clonogenicity induced by dexa-
methasone (4), over expression of Bcl-2 protein completely
failed to inhibit apoptosis induced by the ligation of CD95
(our unpublished data). It has been shown recently that
apoptosis induced by CD95 ligation may proceed either
via activation of CD95-associated FADD and FLICE
(caspase 8), with subsequent caspase activation, a process
which is not suppressed by Bcl-2, or via Daxx and the acti-
vation of the JNK pathway. The Daxx pathway to apopto-
sis is Bcl-2 inhibited in certain cells (43). We are unable to
state how CD95 ligation activated apoptosis occurs in
these CEM-C7A cells. Whatever the precise pathway used
by CD95, unlike the damage signals arising from treat-
ment with etoposide, dexamethasone and staurosporine
(Figs. 1—4), it did not bring about a change in the immu-
nofluorescence of Bak. This supports the idea that the sig-
nalling cascade for the initiation of apoptosis by CD95 dif-
fers from that imposed by the toxins.
When bcl-2 overexpressing CEM-C7A cells (4) were
challenged with etoposide there was only a 30% reduction
in the exposure of the NH2-terminal epitope of Bak, mea-
sured by a fall in the u value (see Results). Thus overex-
pression of bcl-2 somehow either attenuates the damage
signal that reveals the Bak NH2-terminal epitope or it
changes the protein—protein interactions between Bak and
its partners. Bak preferentially binds to Bcl-xL (11) and in
immunoprecipitations of Bak we found no association
with Bcl-2 (Savory, P., unpublished results). However,
Bcl-2 overexpression may change the stoichiometry of the
protein complex containing Bak, but until the components
of that complex have been identified, no mechanistic ex-
planation can be offered to explain the reduction of the
exposure of the Bak NH2 terminus by Bcl-2.
How does the NH2-terminal epitope of Bak, recognized
by Ab-1, become exposed after damage? This could be the
result of direct changes in the conformation of Bak and/or
due to the release of a protein(s) that conceals the NH2-
terminal epitope. Is Bak itself the recipient of damage sig-
nals, perhaps becoming posttranslationally modified, so as
to change conformation? Or, are damage signals received
by accessory proteins, which then bring about the dissocia-
tion of protein(s) from the NH2-terminal domain of Bak,
exposing this epitope? And how do these changes contrib-
ute to the irreversible commitment of the cell to subse-
quent apoptosis? Hsu and Youle (17) reported changes in
epitope availability of murine Bax, again specifically at the
NH2 terminus, after addition of nonionic detergent to cell
lysates. They proposed a model whereby the detergent-
induced changes in Bax epitope availability, observed in
lysates, equated to a change in conformation. This brought
about different patterns of protein—protein interactions.
An open NH2 terminus of Bax promoted Bax homodimer-
ization and heterodimerization with Bcl-xL (17). Addition-
ally, it was suggested that the detergent-induced confor-
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mational change in Bax mimics the conformation that Bax
adopts when it becomes located in the mitochondrial
membrane after translocation from the its monomeric
form in cytosol to a membrane-bound, dimeric form.
When associated with the mitochondrial membrane, Bax-
Bcl-xL heterodimerization may then occur (17). Elegant
studies of murine Bax by Gross et al. (14) confirm that as-
pects of this model for Bax translocation from cytosol to
mitochondria occur in whole cells. Using protein cross-
linking agents they showed that monomeric Bax translo-
cated to mitochondria after an apoptotic stimulus (IL-3
withdrawal) where it then homodimerized. Manipulation
of Bax to enforce homodimerization resulted in transloca-
tion to mitochondrial membranes and in apoptosis (14).
Our results, which examine endogenous human Bak in
intact cells, show that there are distinct differences be-
tween the phenomena observed with Bak compared with
those reported for the murine Bax protein either in lysates
or murine cells. As discussed above, in cells that were
fixed before the use of any detergent, the NH2 terminus of
Bak became available to the antibody Ab-1 after different
types of cell damage. We considered that this might pro-
mote a change in its subcellular location in a manner simi-
lar to that suggested for Bax using cell lysates and, subse-
quently, a change in its association with Bcl-xL (17). The
subcellular fractionation experiments and immunofluores-
cence showed that Bak was not cytosolic before or after
toxin treatment (Fig. 7 A), rather both were more closely
associated with mitochondria, before and after perturba-
tion (Fig. 7 B). Taken together our data show that, unlike
the scenario for murine Bax, an apoptotic stimulus does
not induce a change in subcellular location of Bak. Signals
derived from cellular perturbation by toxins are thus pre-
sumably integrated at intracellular membrane locations.
When we performed immunoprecipitations, with a low
concentration of nonionic detergent present, using either
Ab-1 or the polyclonal antibody to Bak or the polyclonal
antibody to Bcl-xL, probing the subsequent Western blots
showed that Bak-Bcl-xL binding occurred constitutively in
healthy cells (Fig. 8). Lysates prepared from these cells
treated with etoposide to induce maximal unmasking of
the NH2 terminus of Bak, showed a 30—40% decrease in
Bak-Bcl-xL binding (Fig. 8). Increasing the detergent con-
centration from 0.1 to 1% did not alter this result (data not
shown). Therefore, toxin treatment did not recapitulate
for Bak the detergent-mediated promotion of Bax associa-
tion with Bcl-xL, which had been reported using murine
cell lysates (17). Instead, Bak and Bcl-xL appear to be con-
stitutively bound in healthy cells and a proportion of Bak
became dissociated as the cells committed to apoptosis, al-
though it remained membrane bound. The damage in-
duced conformational change in Bak, either at the NH2
terminus itself, or as other domains then undergo subse-
quent topological changes, therefore modulates the stoi-
chiometry of binding of these particular pro- and anti-apop-
totic molecules.
What changes are taking place in this Bak-Bcl-xL com-
plex as the cells commit to apoptosis? And how are these
involved in the commitment of cells to death? Using tran-
sient transfections, a mutational analysis of Bak had sug-
gested that its BH3 domain was required both for binding
to Bcl-xL and for its pro-apoptotic activity, implying that
heterodimerization may be necessary for the induction of
apoptosis (8). Our data are compatible with a model in
which death may be suppressed by heterodimerization
(Bak and Bcl-xL constitutively bound) and where the dis-
sociation of Bak from Bcl-xL correlates with promotion of
apoptosis. Using stably transfected Bak mutants it was
found that cytotoxic drug-induced apoptosis of Fl5.12 cells
was accelerated even when the BH3 domain of Bak was
mutated, an event that abrogated its binding to Bcl-xL
(35). This suggested that Bak works to kill cells indepen-
dently of its binding to Bcl-xL. In a complementary study,
Cheng et al. (7) showed that mutations of Bcl-xL could be
made which retained most of their anti-apoptotic effect
yet did not bind Bax or Bak as effectively in immunopre-
cipitations. These latter studies support growing evidence
that heterodimerization of some of the pro- and anti-apop-
totic members is not required for function (10, 21, 38).
Thus, although the heteromeric binding of these two mole-
cules has been elegantly modeled in vitro (34) it may be
that the Bak responsible for apoptosis is in a cellular pool
different from that bound to Bcl-xL and that this is in-
creased after cell perturbation. The questions of Bak pop-
ulation heterogeneity, is all the Bak associated with Bcl-xL
and whether the Bak-Bcl-xL interaction actually does oc-
cur in vivo, are difficult to resolve. The essential use of de-
tergent to immunoprecipitate these membrane proteins
has been shown to induce conformational changes that
promote heteromeric associations, at least in lysates con-
taining Bax and Bcl-xL (17). It might be argued that the re-
sults of the immunoprecipitations shown in Fig. 8, and our
finding that all the Bak was constitutively associated with
Bcl-xL in untreated cells, may be the consequence of de-
tergent use. Significantly, however, they do show that the
association of Bak with Bcl-xL is changed after toxin treat-
ment. And, critically, we observed a dissociation of pro-
and anti-apoptotic molecules following damage and the
exposure of BakÕs NH2 terminus, in complete contrast
with the association observed between Bax and Bcl-xL that
followed the exposure of the NH2 terminus of Bax (17).
The generality of some of the models for changes in het-
eromerization that presage apoptosis are therefore ques-
tionable.
Two-dimensional electrophoretic analysis of Bak, which
surprisingly showed considerable posttranslational modifi-
cation of Bak, allows speculation that different isoforms
may contribute to a heterogeneity of associations in mem-
branes (Fig. 9). This remains to be determined. We had
originally considered that toxin-induced exposure of an
epitope at the NH2 terminus of Bak may induce or alter
some of the posttranslational modifications of the Bak
protein. This would represent an event whereby there was
an integration of signals arising from different types of cel-
lular damage directly at the Bak molecule itself which
would then contribute to changes in conformation and/or
protein—protein interactions. However, we could detect no
obvious change in the pattern of isoforms after toxin treat-
ment, for example with STS (Fig. 9) or etoposide (data not
shown). This suggests that damage signals are not received
directly by Bak but at some associated protein(s) which
may promote a change in Bak conformation and/or inter-
actions of Bak with other proteins, including Bcl-xL. The
association of accessory protein(s) in a complex with Bak
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is presumably changed once the NH2 terminus has been
exposed.
In summary, FCM has permitted, for the first time, an
analysis of changes in protein conformation and/or of pro-
tein—protein binding in intact cells expressing endogenous
levels of native Bak protein. Events at the NH2 terminus
of Bak involving changes in protein—protein interactions
are suggested to be important for the integration of dam-
age signals and to the subsequent commitment of these
human lymphoid cells to apoptotic death. Precise charac-
terization of the protein(s) bound to the NH2 terminus
may clarify both how damage signals become integrated at
the locus of Bak and how this subsequently commits a cell
to die.
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